U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H11ClN2O5S.C6H15NO
Molecular Weight 447.9353
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FUROSEMIDE DIETHYLAMINOETHANOL

SMILES

c1cc(CNc2cc(c(cc2C(=O)O)S(=O)(=O)N)Cl)oc1.CCN(CC)CCO

InChI

InChIKey=JTMYQHVUVVWDOK-UHFFFAOYSA-N
InChI=1S/C12H11ClN2O5S.C6H15NO/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19;1-3-7(4-2)5-6-8/h1-5,15H,6H2,(H,16,17)(H2,14,18,19);8H,3-6H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C6H15NO
Molecular Weight 117.1896
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C12H11ClN2O5S
Molecular Weight 330.7456
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/furosemide.html

Furosemide, a sulfonamide-type loop diuretic structurally related to bumetanide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome. Furosemide inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic. Furosemide is sold under the brand name Lasix among others.

CNS Activity

Curator's Comment:: furosemide did not cross the barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P05370
Gene ID: 24377.0
Gene Symbol: G6pdx
Target Organism: Rattus norvegicus (Rat)
0.13 mM [IC50]
Target ID: P85968
Gene ID: 1.00360176E8
Gene Symbol: Pgd
Target Organism: Rattus norvegicus (Rat)
0.14 mM [IC50]
0.08 mM [IC50]
52.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LASIX

Approved Use

Edema Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral Furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents.

Launch Date

-1.10678401E11
Primary
LASIX

Approved Use

Edema Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral Furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents.

Launch Date

-1.10678401E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1315.34 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUROSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3014.77 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUROSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.1 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUROSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3.2%
FUROSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
major
yes (co-administration study)
Comment: probe drug substrate for renal transporters OAT1 and OAT3; clinical investigation of a probe drug cocktail containing substrates of key drug transporters (digoxin, furosemide, metformin and rosuvastatin)
Page: 9.0
major
yes (co-administration study)
Comment: probe drug substrate for renal transporters OAT1 and OAT3; clinical investigation of a probe drug cocktail containing substrates of key drug transporters (digoxin, furosemide, metformin and rosuvastatin)
Page: 9.0
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: The time-averaged non-renal clearance (CLNR) of furosemide tended to be faster (but not significantly so) among smokers (3-methylcholanthrene (3-MC) type; a main inducer of CYP1A1/2
Page: 1.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
The loop diuretic torasemide interferes with endothelin-1 actions in the aorta of hypertensive rats.
2001
Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth.
2001
Release of furosemide from multiple-unit and single-unit preparations containing different viscosity grades of sodium alginate.
2001
Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55.
2001 Apr
Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.
2001 Apr
ATP stimulates calcium-dependent glutamate release from cultured astrocytes.
2001 Apr
Systemic sclerosis (scleroderma). A case of recovery of cardiomyopathy after vitamin E treatment.
2001 Apr
Renal concentrating defect in mice lacking group IV cytosolic phospholipase A(2).
2001 Apr
Alternatively spliced isoform of apical Na(+)-K(+)-Cl(-) cotransporter gene encodes a furosemide-sensitive Na(+)-Cl(-)cotransporter.
2001 Apr
Deterioration of left ventricular chamber performance after bed rest : "cardiovascular deconditioning" or hypovolemia?
2001 Apr 10
Distinguishing cochlear pathophysiology in 4-aminopyridine and furosemide treated ears using a nonlinear systems identification technique.
2001 Feb
Renal interstitial atp responses to changes in arterial pressure during alterations in tubuloglomerular feedback activity.
2001 Feb
Brown Norway chromosome 13 confers protection from high salt to consomic Dahl S rat.
2001 Feb
Effect of furosemide on renal excretion of oxypurinol and purine bases.
2001 Feb
Hyponatremia and sensorineural hearing loss in preterm infants.
2001 Feb
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Frusemide or nitrates in acute left ventricular failure.
2001 Jan
Role of the renal kallikrein-kinin system in the development of salt-sensitive hypertension.
2001 Jan
Self-retaining aural speculum: a valuable aid to middle-ear surgery.
2001 Jan
10% hydroxyethyl starch for plasma expansion in the treatment of severe ovarian hyperstimulation syndrome. A case report.
2001 Jan
[Rhabdomyolysis as a rare complication of theophylline poisoning].
2001 Jan 15
Pamidronate and calcitonin as therapy of acute cancer-related hypercalcemia in children.
2001 Jan-Feb
Sensitivity of synaptic GABA(A) receptors to allosteric modulators in hippocampal oriens-alveus interneurons.
2001 Jul
The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2.
2001 Jul 27
The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia.
2001 Jun
Urolithiasis in the low birth weight infant: the role and efficacy of extracorporeal shock wave lithotripsy.
2001 Jun
Angiotensin converting enzyme inhibition worsens the excretory phase of diuretic renography for obstructive hydronephrosis.
2001 Jun
Dynamic characteristics and underlying mechanisms of renal blood flow autoregulation in the conscious dog.
2001 Jun
Perturbation of the pump-leak balance for Na(+) and K(+) in malaria-infected erythrocytes.
2001 Jun
Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites.
2001 Mar
The appropriateness of drug use in an older nondemented and demented population.
2001 Mar
Multi-slice CT urography after diuretic injection: initial results.
2001 Mar
Humoral hypercalcemia of malignancy in squamous cell carcinoma of the skin: parathyroid hormone--related protein as a cause.
2001 Mar
Effect of furosemide on basal lamina anionic sites in guinea pig labyrinth.
2001 Mar
Statistical evaluation of the regulatory guidelines for use of furosemide in race horses.
2001 Mar
Haemoconcentration, shear-stress increase and carotid artery diameter regulation after furosemide administration in older hypertensives.
2001 Mar
Optical imaging reveals cation--Cl(-) cotransporter-mediated transient rapid decrease in intracellular Cl(-) concentration induced by oxygen--glucose deprivation in rat neocortical slices.
2001 Mar
Intraplatelet calcium levels in patients with acute renal failure before and after the administration of loop diuretics.
2001 Mar
Homogeneous enzyme immunoassay for triiodothyronine in serum.
2001 Mar
Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis.
2001 Mar
[Generalized edema following insulin treatment of newly diagnosed diabetes mellitus].
2001 Mar 20
Natriuresis and "dilutional" hyponatremia after infusion of glycine 1.5%.
2001 May
Pulmonary edema: new insight on pathogenesis and treatment.
2001 May
Effects of inhalation of albuterol sulphate, ipratroprium bromide and frusemide on breathing mechanics and gas exchange in healthy exercising horses.
2001 May
Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide.
2001 May
Chloride channels regulate HIT cell volume but cannot fully account for swelling-induced insulin secretion.
2001 May
Nephrocalcinosis induced by furosemide in an adult patient with incomplete renal tubular acidosis.
2001 May
Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients.
2001 May
Interaction of serotonin and cholecystokinin in the lateral parabrachial nucleus to control sodium intake.
2001 May
Ethanol-induced swelling in neonatal rat primary astrocyte cultures.
2001 May 11
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.
2001 May 5
Patents

Sample Use Guides

The usual initial dose of LASIX is 20 to 80 mg given as a single dose. Ordinarily a prompt diuresis ensues. If needed, the same dose can be administered 6 to 8 hours later or the dose may be increased. The dose may be raised by 20 or 40 mg and given not sooner than 6 to 8 hours after the previous dose until the desired diuretic effect has been obtained. The individually determined single dose should then be given once or twice daily (eg, at 8 am and 2 pm). The dose of LASIX may be carefully titrated up to 600 mg/day in patients with clinically severe edematous states.
Route of Administration: Oral
There was a significant reduction in levels of TNF-alpha and IL-6 at a furosemide concentration of 0.5 x 10(-2) M and a reduction in IL-8 levels at 10(-2) M in human peripheral blood mononuclear cells.
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:08:11 UTC 2021
Edited
by admin
on Sat Jun 26 10:08:11 UTC 2021
Record UNII
0WO571ZA9F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FUROSEMIDE DIETHYLAMINOETHANOL
Common Name English
FUROSEMIDE DIETHYLAMINOETHANOL [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
146019556
Created by admin on Sat Jun 26 10:08:11 UTC 2021 , Edited by admin on Sat Jun 26 10:08:11 UTC 2021
PRIMARY
FDA UNII
0WO571ZA9F
Created by admin on Sat Jun 26 10:08:11 UTC 2021 , Edited by admin on Sat Jun 26 10:08:11 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY